Published in Eur J Nucl Med Mol Imaging on April 01, 2010
Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clin Cancer Res (2015) 1.41
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res (2014) 1.39
Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol (2012) 1.22
Engineered antibodies for molecular imaging of cancer. Methods (2013) 1.14
Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med (2014) 1.03
Correlated diffusion imaging. BMC Med Imaging (2013) 0.90
Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med (2012) 0.85
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol (2013) 0.84
Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging. J Nucl Med (2014) 0.83
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol (2015) 0.82
MRl of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS One (2012) 0.81
Molecular imaging in tracking tumor stem-like cells. J Biomed Biotechnol (2012) 0.81
Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumour Biol (2012) 0.81
Positive and negative regulation of prostate stem cell antigen expression by Yin Yang 1 in prostate epithelial cell lines. PLoS One (2012) 0.80
A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Mol Imaging Biol (2014) 0.80
Molecular imaging and fusion targeted biopsy of the prostate. Clin Transl Imaging (2016) 0.75
Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier. Yeast (1991) 14.51
AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging (2003) 8.56
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A (2000) 3.77
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med (2008) 2.03
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med (1990) 1.85
Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm (2000) 1.75
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res (2001) 1.61
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res (2005) 1.43
Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel (2004) 1.29
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1.27
Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J Mol Biol (2004) 1.24
Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res (2008) 1.23
Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol (2003) 1.18
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res (2000) 1.15
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother (2007) 1.13
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res (1988) 1.12
Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res (1992) 1.09
High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A (2009) 1.05
New agents and techniques for imaging prostate cancer. J Nucl Med (2009) 0.96
Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res (1995) 0.95
Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer (2002) 0.94
Molecular imaging of prostate cancer. Methods (2009) 0.92
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci (2010) 5.12
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel (2006) 3.27
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96
Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 2.87
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat Methods (2007) 2.64
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
Hippocampal place cells acquire location-specific responses to the conditioned stimulus during auditory fear conditioning. Neuron (2003) 2.53
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44
Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell (2013) 2.43
Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res (2003) 2.36
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One (2007) 2.28
Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst (2009) 2.28
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer (2014) 2.24
Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer (2007) 2.13
Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A (2007) 2.04
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
SR proteins collaborate with 7SK and promoter-associated nascent RNA to release paused polymerase. Cell (2013) 1.97
FTRAC--a robust fluoroscope tracking fiducial. Med Phys (2005) 1.91
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell (2012) 1.83
Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate (2010) 1.78
Antibodies from phage antibody libraries. J Immunol Methods (2004) 1.75
Kinematic state estimation and motion planning for stochastic nonholonomic systems using the exponential map. Robotica (2008) 1.74
Molecular and cellular approaches to memory allocation in neural circuits. Science (2009) 1.70
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett (2008) 1.62
CaMKII binding to GluN2B is critical during memory consolidation. EMBO J (2012) 1.62
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Antibodies for molecular imaging of cancer. Cancer J (2008) 1.61
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
Antibody vectors for imaging. Semin Nucl Med (2010) 1.60
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res (2002) 1.58
Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell (2013) 1.56
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res (2005) 1.54
The pursuit of a scalable nanofabrication platform for use in material and life science applications. Acc Chem Res (2008) 1.53
Matching and reconstruction of brachytherapy seeds using the Hungarian algorithm (MARSHAL). Med Phys (2005) 1.49
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol (2004) 1.47
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res (2005) 1.43
Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. J Neuroinflammation (2012) 1.40
The impact of orthodontic treatment on the quality of life a systematic review. BMC Oral Health (2014) 1.40
Androgen receptor and invasion in prostate cancer. Cancer Res (2008) 1.40
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab (2010) 1.39
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (2005) 1.38
A multiplex RNA-seq strategy to profile poly(A+) RNA: application to analysis of transcription response and 3' end formation. Genomics (2011) 1.37
Putting fear in its place: remapping of hippocampal place cells during fear conditioning. J Neurosci (2004) 1.36
mTOR Inhibition ameliorates cognitive and affective deficits caused by Disc1 knockdown in adult-born dentate granule neurons. Neuron (2013) 1.35
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol (2009) 1.34
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Solution-phase surface modification in intact poly(dimethylsiloxane) microfluidic channels. Anal Chem (2006) 1.33
Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol (2007) 1.33
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet (2010) 1.31
Quantifying the air pollutants emission reduction during the 2008 Olympic games in Beijing. Environ Sci Technol (2010) 1.30
Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc (2011) 1.30
Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res (2005) 1.29
Gating reaction mechanisms for NMDA receptor channels. J Neurosci (2005) 1.28
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
An internet-based "kinetic imaging system" (KIS) for MicroPET. Mol Imaging Biol (2006) 1.27
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1.27
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel (2004) 1.25
Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas (2005) 1.25
MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer (2013) 1.25
Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res (2008) 1.23
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
LRRC52 (leucine-rich-repeat-containing protein 52), a testis-specific auxiliary subunit of the alkalization-activated Slo3 channel. Proc Natl Acad Sci U S A (2011) 1.22
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res (2004) 1.21
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20
The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol (2008) 1.20
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel (2004) 1.18
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 1.18
Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol (2002) 1.18